News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target. The research ...
Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...
Investing.com -- Lipella Pharmaceuticals Inc (OTC: LIPO) stock plunged 23% after the clinical-stage biotechnology company was delisted from the Nasdaq Capital Market due to rule violations related to ...
The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today.
Alexandria Real Estate Equities, Inc.'s fundamentals remain strong with a 7.4% yield, steady demand, and confident management ...
Parataxis is launching a Bitcoin treasury platform for South Korean institutional investors, which saw Bridge Bio’s stock ...
Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...
However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...
Zealand Pharma A/S’s shares have slid to a near 18-month low, as the Danish biotech’s experimental weight-loss drug faces mounting competition and a long wait ahead for crucial trial results.
The Bajaj Auto Ltd board had recommended a final dividend of Rs 210 per share for FY25. Friday is the record date for the ...
GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results